Showing posts with label ADAP. Show all posts
Showing posts with label ADAP. Show all posts

Thursday, November 19, 2026

New Political Landscape Could Topple CVS Model

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

The 120th Congress may be the one that finally drives the nail in the healthcare model epitomized by CVS, where companies own players at every step of the healthcare process. If nothing else can be said of the November 2026 midterm election season, it’s that a political sea change may improve patient outcomes.


CVS Health
Source: Forbes | Getty

For the uninitiated, CVS Health Group not only owns CVS pharmacies, but also owns:

  • Aetna
    • The health insurance company providing insurance to over 36 million Americans (Aetna, 2026)
  • Oak Street Health
    • A system of primary care clinics serving over 350,000 people across 27 states (Oak St. Health, 2025)
  • CVS Caremark
    • A Pharmacy Benefit Manager (PBM) that negotiates prices for prescription medications, processing nearly 30% of all prescriptions in a given year for more than 110 million plan members in the United States (CVS Caremark, 2026); and
  • Cordavis
    • A Dublin, Ireland-based drug maker that works with existing drug manufacturers to commercialize and/or co-produce biosimilar medications for the U.S. (CVS Health, 2023)

In February 2026, Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) introduced the "Break Up Big Medicine Act," which would:

  • Prohibit a parent company from owning a medical provider or management services organization and a PBM or an insurer;
  • Prohibit a parent company of a prescription drug or medical device wholesaler from owning a medical provider or management services organization;
  • Require that a company in violation of these provisions come into compliance within one year of the bill’s enactment;
  • Create automatic penalties if a company fails to comply in a timely manner, including disgorgement of profits and forced sales of assets;
  • Enable the Federal Trade Commission (FTC), Department of Health and Human Services, Department of Justice (DOJ), state attorneys general, and private parties to bring lawsuits against violators; and
  • Allow the FTC and DOJ to review and block future actions that would recreate the conflicts of interest prevented by the bill.

While there are many reasons why the cost of healthcare services in the United States far outstrips that of other nations—and all for worse health outcomes—the for-profit health insurance scam industry lies at the dead center.


Sen. Elizabeth Warren
Source: Benzinga

CVS, however, is trying to circumvent the outcomes of this legislation by announcing that it is “splitting up” into two entities: one that provides “healthcare solutions” and another that provides pharmacy and other healthcare services (CVS Health, 2026). Senator Warren, however, doesn’t buy that argument, saying the planned split still allows the company to “…own a massive conglomerate and rip people off” (Rawat, 2026).


As ADAP Advocacy has previously argued, the purpose of health insurance in the United States is not to ensure that patients have access to affordable, timely healthcare; the primary function of for-profit health insurance is to make a profit.


But CVS and other health industry companies like UnitedHealth Group and Elevance have gone beyond being the payor, also serving as the provider, prescriber, administrator, and distributor for their enrollees, while taking a cut of the profits at every step.


Because legislation doesn’t carry over from session to session, a bill like the “Break Up Big Medicine Act” will need to be reintroduced in the 120th Congress; this time, what gets introduced may face significantly lower hurdles to make it across the finish line.


That doesn’t mean, however, that the health insurance industry won’t have its own players in Congress. Political Action Committees representing health insurance agencies spent $4.2 million on candidates for the 2026 midterm elections, with both Pete Aguilar (D-CA-33) and current House Minority Leader and House Speaker candidate Hakeem Jeffries (D-NY-08) each receiving over $72k for their 2026 campaigns (Potter & Rettino, 2026). According to the Center for Health and Democracy Education Fund’s Health Insurance Influence Tracker, the following companies donated in the following amounts across the political spectrum:


Health Insurance PAC Donations
Source: Center for Health and Democracy Education Fund

The real question becomes, “How much influence does this kind of funding secure?”


Part of what has made healthcare reform so difficult in the United States is that our political system allows for companies to make relatively unlimited financial donations to candidates while simultaneously serving as the largest employer in many U.S. states. This means hospitals and large health systems wield outsized influence on both state and federal legislatures, threatening to cut off services if legislation doesn’t benefit them first and foremost. Similarly, the for-profit health insurance industry, as well as pharmaceutical and medical device manufacturers, wield outsized influence and have regularly derailed attempts to reform our healthcare system, arguing that it’s “too complex” to move away from the United States’ dysfunctional and barely functional healthcare model to the gold standard universal healthcare model enjoyed by every other major economy on the planet.


The truth is that all of these industries financially benefit when prices are kept artificially high.


Whether those voices will drown out patients' voices in Congress remains to be seen!


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Aetna. (2026). About Us. Hartford, CT: CVS Health Group: Aetna: About Us. https://www.aetna.com/medicare/footers/about-us.html

[2] Center for Health and Democracy Education Fund. (n.d.). Health insurance influence tracker: 2026 midterms. Philadelphia, PA: Center for Health and Democracy Education Fund: Health Insurance Influence Tracker. https://healthinsurancetracker.com/

[3] CVS Caremark. (2026). About Us. Woonsocket, RI: CVS Health Group: CVS Caremark: About Us. https://business.caremark.com/about-us.html

[4] CVS Health. (2023, August 23). CVS Health launches Cordavis. Woonsocket, RI: CVS Health Group: New: PBM. https://www.cvshealth.com/news/pbm/cvs-health-launches-cordavis.html

[5] CVS Health. (2026, November 04). CVS Health announces intent to create two distinct leaders in healthcare. Woonsocket, RI: CVS Health Group: CVS Health: News: Company News. https://www.cvshealth.com/news/company-news/cvs-health-announces-intent-to-create-two-distinct-leaders-in-healthcare.html

[6] Oak Street Health. (2025, May). The Gold Standard of Advanced Primary Care for Medicare Beneficiaries. Chicago, IL: CVS Health Group: Oak Street Health. https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2025/Oak-Street-White-Paper-2025-v2.pdf

[7] Potter, W. & Rettino, J. (2026, October 28). Midterm Money: 97% of Health Insurance Industry Campaign Contributions Went to Incumbents. Substack: Health Care Un-Covered. https://healthcareuncovered.substack.com/p/midterm-money-97-of-health-insurance

[8] Rawat, T. (2026, November 06). Elizabeth Warren Says CVS Is Still Trying To ‘Rip People Off’ With Planned Breakup as Mark Cuban Says Split ‘Changes Nothing For Patients’. Yahoo! Finance: Healthcare: Benzinga. https://finance.yahoo.com/healthcare/articles/elizabeth-warren-says-cvs-still-153007122.html

Thursday, November 12, 2026

340B: A Sticky Situation

By: Guy Anthony, 340B Patient Advisory Committee Chair & Board of Directors Co-Chair, ADAP Advocacy

For more than three decades, the 340B Drug Pricing Program has been characterized as a vital part of America’s healthcare safety net. In ADAP Advocacy’s latest policy paper, "340B Program: The Glue That Should Hold the Healthcare System Together," we argue that 340B should help hold together a fragmented healthcare system for people who are uninsured, underinsured, low-income, or otherwise struggling to access care. I should know because at times, I have been all those people.


Tube of glue with "340B" written on it
Source: ADAP Advocacy

But that glue only works when it sticks to what it was meant to hold together: affordable services available to patients. Right now, 340B is in a “sticky” situation because big hospital systems and mega service providers are intoxicated by their unfettered access to 340B-generated revenues, regardless of whether they’re funding direct services.


Congress created the 340B Drug Pricing Program to extend federal resources and improve patient care. The Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, also known as charity care. What’s particularly striking is that charity care continues to decline year after year. Patients owe at least $220 billion (about $680 per person in the U.S.) in medical debt, and nearly 75% of it is owed to hospitals, with Black and Hispanic communities disproportionately impacted.


For 340B-eligible nonprofit hospitals, it’s hard to defend such practices. ADAP Advocacy’s own research found that 340B-related drug purchases are increasing at the same time medical debt remains a serious burden for Americans. Given this fundamental defect in healthcare coverage, central questions arise:

  • If 340B is designed to expand access and reduce financial burden, then why are patients increasingly unable to afford care?
  • Why is 340B not adequately or even meaningfully addressing this problem?
  • Why is it failing to meet the needs of the uninsured and the underinsured, the very persons it was designed to serve?

More than two-thirds of 340B hospitals provide less charity care than the national average, and more than one-third spend less than 1 percent of total revenue on it. Is that American?


Charity Care Continues to Decline
Source: ADAP Advocacy

If 340B is working as reform denialists claim, we should see proof in patients’ lives, not just hospitals’ bottom lines. Cuba Gooding Jr.’s character in Jerry Maguire demanded, “Show me the money!” I’m asking to show me the patients who can finally afford their medication and get care without going into debt.


So, I keep coming back to one question: where am I, the patient, in all of this?


It gets harder to answer as contract pharmacies expand. Research cited in our white paper (p. 13) found that contract pharmacy growth has been concentrated in affluent, predominantly White neighborhoods, while the share of 340B pharmacies in disadvantaged Black and Hispanic/Latino neighborhoods has declined. The communities most likely to need the program are seeing less of its growth.


I don’t want to see 340B destroyed. I want it fixed. As Alexander Den Heijer wrote, “When a flower doesn’t bloom, you fix the environment in which it grows, not the flower.” Community health centers, Ryan White clinics, hemophilia treatment centers, and other safety-net providers depend on 340B, and patients depend on them. But patients asking how that money is being spent, which is after all generated in their name, shouldn’t be dismissed by those providers.


Protecting the 340B Program cannot mean protecting the status quo. Too often, covered entities absorb 340B revenue into broader hospital budgets instead of reinvesting it in uninsured and underinsured patients.


Patients deserve receipts. Our policy paper calls for mandatory annual reporting on how much 340B Program revenue covered entities generate and where it goes, including charity care, medication assistance, and community services [p. 15].  And if a vulnerable patient generates a 340B discount, that patient should benefit from the 340B price [pp. 14–15].


Rebate
Source: ADAP Advocacy

The proposed retrospective rebate model, which would replace the existing upfront-discount model, would represent a step in the right direction, and one that patients are increasingly embracing because it requires covered entities to be held accountable for how 340B revenues are spent. Interestingly enough, such a model has been in place for over three decades.


Many state AIDS Drug Assistance Programs, or ADAPs, use a rebate model and have increasingly relied on 340B dollars as a share of their total budget. ADAPs now serve more patients, not fewer, despite their dependence on those rebates, providing strong evidence that this works when the discount is tied to a clear mission and measurable outcomes. The National Alliance of State & Territorial AIDS Directors reports those outcomes annually in its monitoring report.


The 340B Program was supposed to help the person living with HIV trying to stay virally suppressed, the uninsured patient terrified of opening another hospital bill, the college student rationing medication, and the Black or Brown family already carrying a disproportionate share of medical debt. For hospitals, they are supposed to help those patients most in need by offering charity care. It should be the standard, not the exception.


I believe in the 340B Program, which is why I want its broken pieces mended. It can still be the glue that holds our safety net together, but only if the discount follows the people who need it most.


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

Thursday, November 5, 2026

A Nursing Shortage with No End in Sight

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

According to a recent Wall Street Journal article citing NSI Nursing Solutions, the turnover rate of registered nurses has increased to 18% in 2025 from 11% in 2010 (Te-Ping, 2026). Arguably, nurses are the backbone of the U.S. healthcare delivery system, so this trend is alarming.


Female nurse sitting on steps with her head crouched in her folded arms
Source: ADAP Advocacy | iStock

The article, entitled “Nurses Are in High Demand—but They’re Quitting in Droves,” presents readers with the conundrum of high-stress jobs in healthcare: pay increases do not lead to better working conditions. And the issue isn’t a shortage of nurses—we’re graduating thousands of new graduates every year, and hospital systems rank among the top five employers in 22 states (Levinson & Hulver, 2025); the issue is that nurses are no longer willing to work in the current hospital environment:


Despite the potential of earning median salaries of $97,550/year, nurses are actively retiring or looking to retire from their positions at higher rates than ever, citing understaffing, verbal abuse, workplace violence, general burnout, and moral injury—where nurses, rather than feeling proud of their work, instead feel they cannot meet their patients’ needs (Costa et al., 2024).


To be clear, this isn't a problem contained to Registered Nurses (RNs) or Licensed Practical Nurses (LPNs)—burnout is common across healthcare, affecting physicians, nurses, caseworkers, and people working in and around the industry.


And the problem will only get worse.


Shortly after the height of the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) released a series of articles focused on the topic of mental health in healthcare workers. They cited the following topline statistics:

  • More than double the number of health workers reported harassment at work in 2022 than in 2018.
  • Nearly half of health workers reported often feeling burned out in 2022, up from 32% in 2018.
  • Nearly half of health workers intended to look for a new job in 2022, up from 33% in 2018 (Nigam et al., 2023).

The solution they proposed reads like a hospital executive’s worst nightmare (Figure 1):


Figure 1 – What Can Employers Do?


MMWR graphic
Source: Nigam et al., 2023

So, what’s so controversial about this seemingly innocuous set of recommendations?


The entire left-hand side of the graphic runs counter to how hospitals have operated for decades.


Let’s examine each of those recommendations:


1. Ensure Adequate Staffing:

Hospitals have been chronically understaffed for decades, particularly with nurses, and those circumstances aren’t getting any better. The Health Resources & Services Administration (HRSA) projects that, in 2027, the U.S. will face a shortage of 107,630 LPNs and 267,900 RNs (HRSA, 2025).


Multiple studies and surveys have shown that RNs repeatedly state that “chronic understaffing” is the primary cause of the issues that drive nurses out of the system. The American Hospital Association—a trade association that “represents 5,000 hospitals and health systems”—lists only three problems: stress, burnout, and retirement:

The report’s omission of chronic understaffing as a root cause is glaring. Executives have made intentional decisions to underinvest in nursing, including understaffed nursing positions, inadequate compensation for permanently employed nurses, and reluctance to create more flexible roles for experienced nurses so they remain in care delivery roles long term. Nursing labor costs comprise a substantial portion of health system budgets, but unfortunately, executives have aimed to shrink costs without recognizing the association of adequate nurse staffing with patient and health system outcomes (Costa et al, 2026).

The reality is that hospital executives—whether at for-profit or non-profit hospitals—place their own salaries above those who are providing actual services to patients and will continue to do so until they are made criminally liable for the injuries to and deaths of patients due to chronic understaffing. It certainly raises the question: how much executive compensation is enough?


And this understaffing doesn’t just lead to worker burnout; it creates conditions that will infuriate already stressed patients who feel their needs are being ignored. This leads us to…


2. Value Worker Safety and Health:


Chronic understaffing means that the nurses currently on site have to contend with staff meetings, significantly high nurse-to-patient ratios (patient caseloads), clinical responsibilities, and unreasonable amounts of medical coding in order to provide health insurers with the information they need to deny process patients’ claims. This means patients often face long wait times for both medical and basic needs, including IV bag replacements, blood draws, and even water. Anyone who’s visited an emergency room in any moderately populated area can attest that, even in settings where time may be a critical factor, it can take hours to even get a bed, much less actually receive care.


In these circumstances—particularly in healthcare settings, where emotions are often already high—patients are more likely to become volatile, especially when they feel like they’re being neglected or ignored. These problems are compounded by growing mistrust in healthcare professionals, stoked by the current Secretary of Health and Human Services, Robert F. Kennedy, Jr. As a result, nurses reported a 26% increase in attacks in 2025 compared with 2017. Another survey found that more than half of nurses reported experiencing verbal threats or aggressive language in the past year, and 27% experienced physical assaults (Kuchno, 2026).


Beyond physical threats to worker health and safety, hospital executives often strictly ration basic equipment and supplies in an effort to cut costs. These moves to decrease line-item costs generally undermine patient care. These cost cuts have led nurses to literally go to other wards to abscond with medical carts and monitors and bring them where they’re needed, rather than leaving them unused elsewhere.


3. Model and Support Taking Time Off


This one is relatively easy to grasp: it’s incredibly easy for management, including executives, to schedule time off; for doctors and nurses, taking time off often requires significant schedule juggling to ensure coverage at hospitals already operating with severe staffing shortages.


Some of this is a failure of imagination. While an 8-hour day is typical in most sectors, it’s not uncommon for nurses to work 12-hour shifts, and a 2008 study found that 35.3% of a nurse’s shift is spent documenting their activities, while just 19.3% of their time is spent directly caring for patients (excluding the administration of medications). Just 7.2% of their time is spent assessing patients and reading vital signs (Hendrich et al., 2008).


It therefore makes sense to schedule more nurses to cover the patient load and hire enough nurses to account for absences. But nurses cost money, and so long as those executives are making money, who cares?


And this is where 340B comes into play.


Man wearing a suit holding lots of cash and smiling
Source: ADAP Advocacy | iStock

The lucrative 340B Drug Pricing Program has served as a cash cow for eligible hospitals, and there are plenty of them. Nationwide, in fact, about 3,000 hospitals participate in the program, accounting for 6 in 10 U.S. hospitals. One primary way 340B funds could improve patient access to care is by hiring additional staff, whether administrative support staff, physicians, or nurses. 


ADAP Advocacy’s own research shows that hospital executives are among the primary “winners” in the 340B Program, as evidenced by huge spikes in their compensation after enrolling in the program. Among the 160 340B-eligible hospitals audited, executive compensation rose by over 200% on average thanks to 340B (ADAP Advocacy, 2026). But that average hides a darker side of this cash windfall, because egregious examples include a 1,133.42% pay bump for Sutter Valley Hospitals’ executive (Sacramento, CA), a 1,421.15% increase for Yale New Haven Hospital’s executive (New Haven, CT), and a 2,803.81% hike for Baptist Memorial Hospital Golden Triangle’s executive (Columbus, MS) (ADAP Advocacy, 2026). 


Does a hospital CEO seriously need to make $6,471,125, $8,792,821, or $14,336,581? To improve patient care, wouldn’t spending $1 million to hire 10 additional nurses have a greater impact? Yet nurses across the country still say they face unmanageable shortages that are affecting patient outcomes. Interesting, isn’t it?


Hospitals are fighting desperately to stop reforms to the 340B Program that would require them to report how they utilize 340B-generated revenues. And anyone fighting that hard to prevent transparency can’t be doing so for any good reason. The current nursing shortage is driven by multiple triggers, but we do know at least one solution: hire more nurses!


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] ADAP Advocacy Association (2026). The 340B Drug Rebate Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities. 340B Map. https://340bmap.org/

[2] Costa, D. K., Valley, T. S., & Friese, C. R. (2024, May). Addressing the Nursing Workforce Crisis Through Nurse-Physician Collaboration. JAMA Internal Medicine, 184(5), 463-464. https://doi.org/10.1001/jamainternmed.2024.0183

[3] Health Resources & Services Administration. (2025, December 18). Workforce Projections. Rockville, MD: United States Department of Health and Human Services: Health Resources & Services Administration: Health Workforce: National Center for Health Workforce Analysis. https://data.hrsa.gov/topics/health-workforce/nchwa/workforce-projections

[4] Hendrich, A., Chow, M. P., Skierczynski, B. A., & Lu, Z. (2008). A 36-hospital time and motion study: how do medical-surgical nurses spend their time? The Permanente Journal, 12(3), 25–34. https://doi.org/10.7812/tpp/08-021

[5] Kuchno, K. (2026, October 20). Bedside nurse turnover reaches 18%. Chicago, IL: Becker’s Hospital Review: Workforce. https://www.beckershospitalreview.com/workforce/bedside-nurse-turnover-reaches-18/

[6] Levinson, Z. & Hulver, S. (2026, May 21). Mapping Hospital Employment By State. San Francisco, CA: KFF: Medicaid. https://www.kff.org/medicaid/mapping-hospital-employment-by-state/

[7] Nigam J. A., Barker R. M., Cunningham T. R., Swanson N. G., & Chosewood L.C. Vital Signs: Health Worker–Perceived Working Conditions and Symptoms of Poor Mental Health—Quality of Worklife Survey, United States, 2018–2022. Morbidity & Mortality Weekly Report, 72(44), 1,197-1,205. http://dx.doi.org/10.15585/mmwr.mm7244e1

[8] Te-Ping, C. (2026, October 19). Nurses Are in High Demand—but They’re Quitting in Droves. New York, NY: Wall Street Journal: Health. https://www.wsj.com/health/healthcare/nurses-are-in-high-demandbut-theyre-quitting-in-droves-d8ead94f

Thursday, October 22, 2026

'ADAP Saves Lives: End the Wait' National Advocacy Campaign Moves Into Full Gear

By: Michelle Anderson, MA, Grassroots Advocacy & Patient Storytelling Consultant, ADAP Advocacy

For people living with HIV, access to medication is personal…deeply personal. It means staying healthy, caring for family, working, and planning for the future. When access is threatened, discussion of program funding becomes a much more immediate question: Will my next prescription be available when I need it?

The AIDS Drug Assistance Program (ADAP) exists to help eligible people living with HIV/AIDS access treatment they otherwise could not afford. For those of us who depend on this assistance, or previously relied on it, qualifying should provide some reassurance. The return of ADAP waiting lists has brought back a fear that many longtime advocates remember. Qualifying for assistance does not bring peace of mind when the assistance itself is out of reach.

Status of ADAP Budgets for the Current RWHAP Part B Fiscal Year (ending March 31, 2027) Fifteen ADAPs report a projected deficit for the current fiscal year — six minor (<5% of total operating budget) and nine significant (≥5%). This represents a decrease from the April 2026 ADAP Watch, which reported 19 deficit-projecting programs. Four programs that reported deficits in April have since resolved them — Arizona, New Jersey, Washington, D.C., and Wisconsin. Two programs are newly reporting deficits in July: Georgia and Texas. Twenty-three ADAPs report balanced budgets, and five anticipate a surplus.
Source: NASTAD

After 13 years, people living with HIV/AIDS in two states are once again being denied access to care and treatment because ADAP is running out of money. According to the National Alliance of State and Territorial AIDS Directors’ ADAP Watch, Iowa and Utah have ADAP waiting lists.

These experiences are why patient voices must remain central to the response. People living with HIV understand what consistent treatment makes possible. Their knowledge can help lawmakers understand the consequences of funding decisions and recognize the need to act before people lose access to care.

A Renewed Campaign Built on Years of Advocacy

ADAP Advocacy’s 'ADAP Saves Lives: End the Wait' national advocacy campaign is moving full gear again. Created in 2009 in response to 99 clients on ADAP waiting lists, the campaign reactivated in June 2026. Its message remains unchanged: no one should be told to wait for lifesaving medication.

Over the last several months, much of the campaign’s work has happened behind the scenes. ADAP advocacy has been rebuilding grassroots networks across six key states while simultaneously reconnecting with advocates and strengthening the relationships needed to move people into action. That work takes conversations, follow-up, and trust. It also means making sure people living with HIV/AIDS help shape the response. It also means ADAP Advocacy offering help to advocates in these states, rather than trying to march in and dictate strategy.

ADAP Saves Lives: End the Wait
Source: ADAP Advocacy

The 'End the Wait' campaign has also created opportunities for communities to come together and speak up. Pennsylvania is one of the six key states where the campaign is focused on protecting ADAP access as funding shortfalls force eligibility and drug formulary restrictions that threaten care. These cost containment strategies are the invisible waiting lists in this struggle. In Pittsburgh, ADAP Advocacy held a Community Town Hall Meeting and a subsequent Health Fireside Chat focused on these challenges and their impact on people who depend on ADAP. The campaign’s newest public service announcement brought those conversations to a wider audience with a clear message: access to lifesaving HIV medication must be protected. These efforts are helping turn public awareness into support for action.

Connecting Information with Action

As the 'End the Wait' campaign expands, a newly announced interactive AIDS Drug Assistance Program Grassroots Advocacy Hub gives advocates a central place to find information and coordinate their efforts. It brings state-focused updates and campaign materials together so patients and community partners can better understand the issues and share them with others. Resources include advocacy and social media toolkits, communication and calendar-sharing tools, and other resources that organizations and individuals can use with their networks. Having these materials in one place makes it easier to bring accurate information into community conversations and keep attention on the need for reliable access to treatment.

The AIDS Drug Assistance Program Grassroots Advocacy Hub features resource centers for Florida, Illinois, Iowa, Pennsylvania, Texas, and Utah, at least to start, helping advocates take the next step. The Congress lookup identifies Members of Congress, so people know which offices to contact, while the global calendar highlights upcoming events and opportunities to participate. These features connect learning about an issue with practical ways to act. The hub is available online at https://www.adapadvocacy.org/adap-saves-lives.

Building A Collective Demand for Treatment Access

ADAP Advocacy’s 'ADAP Saves Lives: End the Wait' national advocacy campaign focuses on convincing Congress to fully fund the AIDS Drug Assistance Program. To that end, a national sign-on letter calling for an additional $175 million is now being circulated for signatures!

Letter
Source: liveabout dot com

Protecting access to HIV treatment takes support from across the community. Housing providers, food assistance programs, mental health organizations, reproductive health advocates, disability rights groups, and faith communities serve many of the same people. By adding their names to the national letter, these organizations can join a collective call to protect ADAP’s across the country.

The letter, in part, reads:

"We are concerned that federal investment hasn’t kept pace with the program's changing fiscal demands. Even as more clients enroll and healthcare costs climb, federal funding for ADAPs has remained essentially flat since 2014. In inflation-adjusted terms, that erosion has reduced the federal investment's purchasing power to roughly the level it had in 1999. As a result, states are resorting to lowering income limits, restricting access to antiretroviral treatment options, and removing access to medications used to treat comorbid conditions, including diabetes, cardiovascular disease, and chronic kidney disease."

Click here to read the full letter.

Click this link to add an organization to the national sign-on letter. Signatures are limited to organizations, not individuals. Organizational signatories are being added on a rolling basis.

Individuals can use the patient resource center’s advocacy widget to contact their legislators and urge them to fully fund ADAP.

Bringing the Conversation to Texas

The campaign’s organizing efforts will continue with a virtual statewide Texas Community Town Hall Meeting on Wednesday, November 18, 2026, from 7:00 pm to 8:00 pm CENTRAL TIME. The meeting is open to the public and will focus on access-to-care and treatment challenges involving the Texas HIV Medication Program, the state’s ADAP.

Patients, providers, community organizations, families, and allies across Texas are encouraged to participate. Their experiences can help identify barriers, inform advocacy, and keep the needs of people living with HIV at the center of the discussion.

Source: ADAP Advocacy

Visit ADAP Advocacy's Events page to register: https://www.adapadvocacy.org/events/2026/townhall/texas.

Conclusion

The 'ADAP Saves Lives: End the Wait' national advocacy campaign, centered around patients and their lived experiences with ADAP, ensures that the voice of people living with HIV/AIDS shall always be at the table and the center of the discussion. HIV advocates have faced this uncertainty before, and they’ve always risen to the challenge. That is what needs to happen now! ADAP Advocacy is doing its part by building state grassroots efforts, making user-friendly advocacy resources and tools available, hosting community town hall meetings, spearheading an organizational national sign-on letter, and complementing the work already being done at the state and community levels.

ADAP SAVES LIVES… END THE WAIT!

Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

Thursday, October 8, 2026

340B: The Glue That Should Hold Our Healthcare System Together

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

In June 2026, ADAP Advocacy released its latest policy paper—340B Program: The Glue That Should Hold Our Healthcare System Together—focusing on the explosive growth of the 340B Program from just 1,000 covered entities (CEs) and 503 contract pharmacies (CPs) in 1992 to over 53,000 CEs and 34,840 CPs in 2024. In addition to examining this growth and its causes, ADAP Advocacy also provided concrete recommendations to ensure the 340B Program can function in perpetuity (Macsata, et al., 2026). The policy paper is the latest in a series supporting the organization's argument that the 340B Program is too big to fail.


Glue bottle with "340B" label
Source: ADAP Advocacy

ADAP Advocacy argues that, because the 340B Program spans more than 42,000 healthcare organizations and 32,000 pharmacies, it should be the glue that holds our healthcare system together. Instead, the 340B program has essentially become a slush fund for unscrupulous CEs—primarily hospitals—that lines executives’ pockets while cutting corners, costs, and services for both staff and patients. That’s not to suggest the program isn’t vitally important, or that there aren’t plenty of good actors…CEs…in the 340B space, because it is, and there are. The fact of the matter is a healthcare program of this size and magnitude cannot be entrusted to good faith alone; rather, improved transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients.


Primary Drivers of Growth:


ADAP Advocacy identified several key drivers of growth in the 340B program, including:

  • The expansion of eligibility categories;
  • The expansion of large health systems;
  • The growing utilization by CEs of off-site clinics and child sites; and
  • The explosive growth of Pharmacy Benefit Managers (PBMs) and contract pharmacies operating in the American healthcare space as third-party administrators for CEs

Policy Proposals


ADAP Advocacy also recommended several policy proposals to address the myriad issues facing the program, including:

  • The implementation of a program-wide rebate model, in which drugs are purchased at full price up front, and rebates are provided by manufacturers at a later date;
  • The consideration of a rebate “sales draw” under the program-wide rebate model that accounts for agencies with smaller annual operating revenues (e.g., those with less than $2 million);
  • Mandatory reporting requirements for CEs, including how revenues have been used to improve patient care, reduce drug costs, or expand community services;
  • Clearly defining “patient” in the statute—who qualifies as a patient, and which purchases qualify for 340B rebates; and
  • Establishing an enforcement mechanism with real teeth and penalties ranging from civil monetary penalties to loss of 340B eligibility.

Each proposal is designed to ensure 340B revenues are used for patients in need, as intended by those who created the program. And these changes are long overdue.


Scale with money on one side and Rx drugs on the other side
Source: ADAP Advocacy | iStock

In 2025, 340B drugs exceeded $179.5 billion in list prices, with hospitals as the biggest cost driver (Martin et al, 2026). The 340B Program is immensely significant, and rising waste, fraud, and abuse pose an increasing risk. Because the American healthcare system is highly interdependent, a weakness in one sector can have widespread repercussions, making the 340B Program's impact especially important. 


Research published in September 2026 by the Pioneer Institute found that hospitals participating in the 340B Program spent an average of just 2.16% of their operating expenses on charity care, compared to 2.82% at non-340B hospitals. It also found that 340B hospitals spent just 1.6% of operating expenses on care for uninsured patients, compared with 2.26% at non-340B hospitals (Popovian et al., 2026).


Popovian et al. are quick to point out that their findings do not suggest that participating in the 340B Program “causes” hospitals to provide less charity care or care at cost; rather, their findings demonstrate that the 340B Program’s drug discounts, savings, and revenues do not reliably translate into providing more help for patients (either in terms of healthcare provision or lower costs), and that current reporting requirements are insufficient to ensure that 340B revenues are being appropriately utilized in ways that comport with either the letter or intent of the statute.


Pioneer Institute report cover
Source: Pioneer Health

Last month, ADAP Advocacy launched a national advocacy campaign focused on the data and findings of its most recent 340B white paper, including infographics, social media posts, op-eds, and video content. The campaign is patient-centric in that it informs patients, regardless of their chronic health condition or rare disease, why they can no longer sit on the sidelines and watch the pharmaceutical industry and big hospital systems duke it out over what is in our best interest. Nothing about us, without us!


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Macsata, B. M., Anthony, G., Hopkins, M. J., Sosa, J. (2026, June). 340B Program: The Glue That Should Hold Our Healthcare System Together. Nags Head, NC: ADAP Advocacy: Policy Center: 340B: Policy Papers. https://www.adapadvocacy.org/s/2026_ADAP_Project_RW_340B_Asset_32_340B_Glue_Should_Hold_Healthcare_Together_061526.pdf

[2] Martin, R., Karne, H., Zen, S. (2026, June), The Size and Growth of the 340B Program in 2025. IQVIA. https://www.iqvia.com/-/media/iqvia/pdfs/us/white-paper/2026/iqvia-size--growth-of-340b-in-2025-white-paper-2026.pdf

[3] Popovian, R., Sydor, A. M., Czubaruk, K., Walker, M., & Smith, W. (2026, September 24). The 340B Accountability Gap: Charity Care, Uncompensated Care, and Medicaid Patient Volume Among 340B and Non-340B Hospitals: What the Data Mean for 340B Accountability and Reform. Boston, MA: The Pioneer Institute: Pioneer Health. https://pioneerinstitute.org/wp-content/uploads/2026/09/2026-09-08-Cancer-Care-340B-Paper.pdf

Thursday, October 1, 2026

CDC Releases New Information About People Living With HIV/AIDS

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

The Centers for Disease Control and Prevention (CDC) released its latest update to the Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection in September 2026. These data represent findings from people living with HIV/AIDS (PLWHA) collected in 2024, and could point to significant trouble ahead for PLWHA (CDC, 2026).


HIV Data Release
Source: CDC

Key Findings and Discussion:


While 80% of respondents were prescribed antiretroviral therapy (ART) to treat their HIV, only 63% reported taking every dose as prescribed. Among those who missed doses, 22.7% missed doses for 1 to 2 days, 10.2% for 3 to 5 days, 1.5% for 6 to 10 days, and 2.3% for 11 or more days. The most commonly reported reasons for not taking medications included:

  • Forgetting to take them (69.1%)
  • Changes in daily routines or travel (42.3%)
  • Falling asleep early or oversleeping (38.4%)
  • Feeling depressed or overwhelmed (21%)
  • Problems getting prescriptions or refilling medications (18.5%)
  • The person didn’t feel like taking them (14.1%)
  • Alcohol or drug use (10.3%)
  • Problems paying for medications (6.9%)
  • In the hospital or too sick to take medications (6.6%)
  • Difficulties with medication side effects (5.8%)

When disaggregated by sex, Female respondents were slightly more likely to be adherent to treatment (66.2%), while 62.5% of Males reported being adherent.


When disaggregated by race, Multiracial Americans were the least likely to be treatment adherent (59.5%), followed by Black Americans (62%), Hispanic/Latine Americans (63.1%), and White Americans (65.6%). Asian Americans had the highest rate of treatment adherence, at 70.6%.


When disaggregated by age, adults aged 50+ were most likely to be treatment adherent (69.9%), followed by those aged 40-49 (58.3%) and those aged 18-29 (53.6%). Adults aged 30-39 were the least adherent, at 50.6%.


These data are particularly problematic, as failure to adhere to treatment regimens can result in the mutation of the virus to become resistant to specific ARTs or drug classes, making HIV harder to treat and limiting future treatment options. Additionally, nonadherence to ART regimens can leave the virus unsuppressed, increasing the likelihood of transmitting it to others (HIV dot Gov, 2026).


Importance of HIV Medication Treatment Adherence
Source: Marley Drug

How to Improve Treatment Adherence


The HIV treatment landscape has changed significantly over the past twenty years. While treating HIV once required patients to take and keep track of multiple pills a day (or daily injections), single-pill oral regimens became the norm in the 2010s, and now, we have long-acting injectable (LAI) medications that can be delivered monthly or every other month.


A recent study published in The New England Journal of Medicine found that patients treated with LAIs were significantly less likely to experience regimen failure (n = 29; 19%) than patients taking a standard oral regimen (n = 55; 36%). While most regimen failures in the standard group resulted from virologic failure (58.2%), treatment discontinuation or abandonment caused regimen failure in the LAI group (82.6%). At the 48-week mark, regimen failure was 22.8% in the LAI group and 41.2% in the standard oral regimen group, indicating that LAIs are a key component to improve treatment adherence and virologic suppression (Rana et al., 2026)


ADAP Advocacy’s own research found that 52.3% of patients who responded to a 2024 survey would prefer LAI treatment regimens over oral regimens (Johnson et al., 2024).


Long-acting injectables needle
Source: ADAP Advocacy

Quality of Life and HIV


Additional findings of the MMP found that structural challenges continue to negatively impact PLWHA, with respondents reporting hunger or food insecurity (22%), unstable housing or homelessness (20%), and unemployment (15%) as being primary drivers of poor physical, mental, and emotional health. Moreover, many PLWHA reported unmet needs for ancillary services that could improve living conditions and well-being, including access to dental care (24%), meal or food service assistance (15%), and stable sheltering or housing services (15%).


Trouble Ahead


The real concern in these data is not the data themselves, but that they were gathered before the Trump Administration took wrecking balls to nearly every aspect of public health provision and services. With state ADAP programs facing increasing budgetary shortfalls that could result in constriction of state programs (Hopkins, 2026), the forthcoming Medicaid implosion that the Trump Administration and its allies in Congress forced through in the One Big Beautiful Bill Act (Hopkins, 2025), and exploding costs of living related to the ongoing war against Iran and nonsensical tariffs, including skyrocketing costs of fuel, diesel, food, goods, and services (Wile & Murphy, 2026; Zahn, 2026), PLWHA are going to be squeezed more than ever. The reality is that patients living with HIV are going to be significantly worse off financially and are likely to face significantly higher barriers to accessing not only HIV care and treatment, but basic necessities, like food, shelter, and transportation.


While we should have been preparing for this for a while, many of us were caught flat-footed by the wholesale destruction being wrought by the Trump Administration. Hopefully, we will be able to course correct enough to avoid the majority of the devastation many are predicting.


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Centers for Disease Control and Prevention. (2026, September 10). Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection. Atlanta, GA: United States Department of Health and Human Services: Centers for Disease Control and Prevention: National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention: Division of HIV Prevention: HIV Data: Medical Monitoring Project. https://www.cdc.gov/hiv-data/mmp/behavioral-clinical-characteristics-pwh.html

[2] HIV dot Gov. (2026, September 24). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Rockville, MD: United States Department of Health and Human Services: Office of Infectious Disease and HIV/AIDS Policy: HIV dot Gov: Clinical Info: Guidelines. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/interruption-antiretroviral-therapy

[3] Hopkins, M. J. (2025, July 30). Preparing for One Big Beautiful Disaster. Washington, DC: PlusInc: Blog. https://www.plusinc.org/blog/one-big-beautiful-disaster

[4] Hopkins, M. J. (2026, September 24). ADAP: A House of Cards Waiting to Fall. Nags Head, NC: ADAP Advocacy: ADAP Blog. https://adapadvocacyassociation.blogspot.com/2026/09/a-house-of-cards-waiting-to-fall.html

[5] Johnson, R. D., Hopkins, M. J., Laws, J., & Macsata, B. M. (2024). HIV Long-Acting Injectables: Patient access considerations for injectable HIV therapies and injectable HIV Pre-Exposure Prophylaxis. Nags Head, NC: ADAP Advocacy. https://www.adapadvocacy.org/s/2024_ADAP_Project_Long_Acting_Injectables_Final_Report_062524-wgxy.pdf

[6] Rana, A. I., Zheng, L., Castillo-Mancilla, J., Bao, Y., Sieczkarski, S., Brooks, K. M., Lake, J. E., Fichtenbaum, C., Heath, S. L., Belaunzaran-Zamudio, P. F., Klingman, K., Fox, L., Morton, T., Stirratt, M., Li, J. Z., Acosta, E. P., Venuto, C., Galárraga, O., Shoptaw, S., Wohl, D., … ACTG A5359 LATITUDE Trial Team. (2026). Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. The New England journal of medicine, 394(9), 858–871. https://doi.org/10.1056/NEJMoa2508228

[7] Wile, R. & Murphy, J. (2026, September 23). The U.S. economy before and after the Iran war, in five charts. New York, NY: NBC News: Business: Economy. https://www.nbcnews.com/business/economy/us-economy-iran-war-five-charts-rcna598412

[8] Zahn, M. (2026, August 25). Tariffs will cost US households over $1,000 a year, Yale Budget Lab says. Burbank, CA: ABC: ABC News: Business. https://abcnews.com/Business/tariffs-cost-us-households-1000-year-yale-budget/story?id=135945432

Thursday, September 24, 2026

ADAP: A House of Cards Waiting to Fall

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

Did you know that Federal funding for the AIDS Drug Assistance Program (ADAP) accounted for just 29% of the 2024 national ADAP budget? Did you know that Congress has not appropriated any new money for the ADAP budget in over a decade?


It’s true!


ADAP Earmark in Nominal Dollars and Adjusted for Inflation (1996 dollars)
Source: KFF

According to the National Alliance of State and Territorial AIDS Directors (NASTAD), federal appropriations for ADAP account for a vanishingly small percentage of the national ADAP budget (NASTAD, 2026).


Since the establishment of the Ryan White HIV/AIDS Program in 1990, Congress has appropriated funds specifically to address the provision of medications to treat HIV/AIDS for patients who might otherwise be unable to afford them. But the spending power of those federal dollars has fallen significantly over the past twenty years.


In Fiscal Year 2004, federal appropriations accounted for 61%, state-level funding for 19%, and drug rebates for 12%.


Fast forward to 2024—the most recent year for which data are available—and that funding model is fundamentally different:


In FY2024, drug rebates accounted for 52%, federal funding for 29%, and state-level funding for just 4%.


According to a presentation delivered by NASTAD’s Tim Horn at ADAP Advocacy’s recent Health Fireside Chat in Pittsburgh, Pennsylvania, federal funding for the AIDS Drug Assistance Program has been stalled at ~$900 million annually for a program that costs $2.7 billion (Macsata & Hopkins, 2026).


And now, yet another crisis has landed itself in ADAP's proverbial lap. After 13 years, people living with HIV/AIDS in two states are once again being denied access to care and treatment because ADAP is running out of money. According to NASTAD’s ADAP Watch, Iowa and Utah have ADAP waiting lists.


Fifteen ADAPs report a projected deficit for the current fiscal year — six minor (<5% of total operating budget) and nine significant (≥5%). This represents a decrease from the April 2026 ADAP Watch, which reported 19 deficit-projecting programs. Four programs that reported deficits in April have since resolved them — Arizona, New Jersey, Washington, D.C., and Wisconsin. Two programs are newly reporting deficits in July: Georgia and Texas. Twenty-three ADAPs report balanced budgets, and five anticipate a surplus.
Source: NASTAD

How did we get here?


Put plainly, ADAP has been largely forgotten by federal and state legislators, in much the same way that many people seem to have forgotten that HIV/AIDS still exists. Unless someone is in front of them banging the drum that people are still being diagnosed and living with HIV/AIDS, it’s out of sight, out of mind.


In many ways, the reluctance of HIV advocacy organizations to actively and vocally push for increases to the ADAP earmark comes from a place of fear: fear that, by reminding legislators that HIV/AIDS exists, it places HIV funding at risk of further funding cuts.


And that fear isn’t without merit; since resuming office in January 2025, Donald Trump’s administration has actively worked to dismantle and defund HIV services at home and abroad.


In 2025, the Trump Administration:

  • Issued a stop-work order that froze all programming and services for the President’s Emergency Plan for AIDS Relief (PEPFAR), which halted all work in the field, including the provision of antiretroviral therapy (ART);
  • Issued a limited waiver for PEPFAR that allowed only ‘life-saving HIV services,” which excluded most HIV prevention services;
  • Dissolved the USAID program that administered the PEPFAR program;
  • Canceled funding for hundreds of programs that included HIV activities (KFF, 2026)

Donald J. Trump
Source: STAT | Getty Images


Beyond pulling the rug out from under PEPFAR, the Trump Administration has gone further by announcing it will not renew $46 million in funding for Community-Based Organizations (CBOs) to provide HIV testing, linkage to care, referrals to pre- and post-exposure drug treatment, and outbreak response (Cohen, 2026). Instead, those funds will be redirected to state and local health departments—an effort to control how the funds are used and who they reach, avoiding funding for “Diversity, Equity, and Inclusion.”


The President’s 2027 budget also proposed eliminating $800 million from the Centers for Disease Control and Prevention’s HIV prevention funding (Cohen, 2026). Additionally, it proposed the elimination of the Housing Opportunities for People with AIDS (HOPWA) program—which serves over 100,000 households annually (Bennett & Hannon, n.d.).


In context, those cuts, whether they’re actual or proposed, paint an even bleaker picture of the state of ADAPs at the federal level. Even though more clients are enrolling and healthcare costs are climbing, federal funding for ADAPs hasn't really grown over the past decade. This means ADAPs have the same purchasing power as they did in 1999, once inflation is accounted for. HIV advocacy needs to remind Congress of the inherent value of this program.


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Bennett, R. & Hannon, B. (n.d.) Housing Opportunities for Persons with AIDS (HOPWA). National Low Income Housing Coalition. https://nlihc.org/sites/default/files/AG-2025/4-135_Housing-Opportunities-for-Persons-with-Aids-HOPWA.pdf

[2] Cohen, A. (2026, July 20). Trump administration puts kibosh on HIV prevention funding. Washington, DC: Roll Call: Policy. https://rollcall.com/2026/07/20/trump-administration-puts-kibosh-on-hiv-prevention-funding/

[3] KFF. (2026, August 06). The Trump Administration’s Foreign Aid Review: Status of PEPFAR. San Francisco, CA: KFF: Global Health Policy. https://www.kff.org/global-health-policy/the-trump-administrations-foreign-aid-review-status-of-pepfar/

[4] Macsata, B. M. & Hopkins, M. J. (2026, August 20). Fireside Chat Retreat in Pittsburgh, PA Tackles Emerging Crisis Facing AIDS Drug Assistance Programs. Washington, DC: ADAP Advocacy: ADAP Blog. https://adapadvocacyassociation.blogspot.com/2026/08/fireside-chat-retreat-in-pittsburgh-pa.html

[5] National Alliance of State and Territorial AIDS Directors. (2026a). 2026 National Ryan White HIV/AIDS Program Part B ADAP Monitoring Project Annual Report: Stabilizing the Safety Net: Stewardship and Outcomes in a Volatile Landscape. Washington, DC: National Alliance of State and Territorial AIDS Directors. https://nastad.org/2026-rwhap-part-b-adap-monitoring-report